NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated. - Freeman TJ; George TJ; Jacobs SA; Yothers G; Kolevska T; Feng H; Lipchik C; Maley S; Song N; Srinivasan A; Finnigan M; Wade JL 3rd; et al. (Cancer chemotherapy and pharmacology, 2025)